Penny Tom Sells 65,000 Shares of Equillium (NASDAQ:EQ) Stock

Key Points

• Insider selling: Penny Tom sold 65,000 Equillium shares at an average of $2.95 each, trimming their stake by 50%. The trade was made under a pre-arranged Rule 10b5-1 plan.
• Stock performance and earnings: Equillium shares rose 2.1% to $2.90, trading above both the 50-day and 200-day moving averages. The company also recently reported a quarterly loss of $0.06 per share, missing analyst expectations.
• Analyst sentiment remains mixed but optimistic overall: Leerink Partners upgraded the stock to outperform with a $6 target, while other firms issued a range of buy, hold, and sell views. The consensus rating is currently Moderate Buy with a $7.57 price target.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) insider Penny Tom sold 65,000 shares of the company's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $2.95, for a total transaction of $191,750.00. Following the transaction, the insider owned 65,000 shares of the company's stock, valued at approximately $191,750. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Equillium Trading Up 2.1%

Shares of NASDAQ:EQ traded up $0.06 during midday trading on Friday, reaching $2.90. 853,917 shares of the company were exchanged, compared to its average volume of 480,896. The business's fifty day moving average is $2.09 and its two-hundred day moving average is $1.63. Equillium, Inc. has a one year low of $0.27 and a one year high of $3.10. The stock has a market cap of $183.37 million, a PE ratio of -9.06 and a beta of 1.67.

Equillium (NASDAQ:EQ - Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). As a group, sell-side analysts expect that Equillium, Inc. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

EQ has been the subject of several research reports. Leerink Partners upgraded shares of Equillium from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $1.00 to $6.00 in a research report on Thursday. Zacks Research upgraded shares of Equillium to a "hold" rating in a report on Thursday, February 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Equillium in a report on Friday, March 27th. Wall Street Zen lowered shares of Equillium from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Finally, Raymond James Financial restated a "strong-buy" rating and issued a $7.00 target price on shares of Equillium in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.57.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in EQ. Aberdeen Group plc purchased a new position in Equillium in the 3rd quarter worth about $543,000. Vanguard Group Inc. increased its stake in Equillium by 59.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company's stock worth $1,879,000 after buying an additional 489,855 shares during the period. Persistent Asset Partners Ltd purchased a new position in Equillium in the 3rd quarter worth about $99,000. Two Sigma Investments LP purchased a new position in Equillium in the 3rd quarter worth about $190,000. Finally, ADAR1 Capital Management LLC purchased a new position in Equillium in the 3rd quarter worth about $7,951,000. Hedge funds and other institutional investors own 27.05% of the company's stock.

Key Headlines Impacting Equillium

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

About Equillium

Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.